Optimer Pharmaceuticals to Present at 23rd Annual Oppenheimer Healthcare
JERSEY CITY, N.J., Dec. 5, 2012
JERSEY CITY, N.J., Dec. 5, 2012 /PRNewswire/ --Optimer Pharmaceuticals, Inc.
(NASDAQ: OPTR) today announced that the Company will present at the 23^rd
Annual Oppenheimer Healthcare Conference on Wednesday, December 12, 2012 at
2:45 PM Eastern Time in New York and provide a business overview and update.
A live audio webcast of the presentation will be accessible on the Investors
page of the Company's website at www.optimerpharma.com.Replays of the
presentation will be available at the same location for 30 days following the
Optimer Pharmaceuticals, Inc.is a global biopharmaceutical company focused on
developing and commercializing innovative hospital specialty products that
have a positive impact on society. Optimer developed DIFICID® (fidaxomicin)
tablets, anFDA-approved macrolide antibacterial drug for the treatment
ofClostridium difficile-associated diarrhea (CDAD) in adults 18 years of age
and older and is commercializing DIFICID in the US and Canada. Optimer also
received marketing authorization for fidaxomicin tablets in theEuropean
Unionwhere its partner,Astellas Pharma Europe, is commercializing
fidaxomicin under the trade name DIFICLIR™. The Company is exploring
marketing authorization in other parts of the world whereC. difficilehas
emerged as a serious health problem, includingAsia. Additional information
can be found at http://www.optimerpharma.com.
Optimer Pharmaceuticals, Inc.
David Walsey, VP of Investor Relations and Corporate Communications
Jason I. Spark, Senior Vice President
SOURCE Optimer Pharmaceuticals, Inc.
Press spacebar to pause and continue. Press esc to stop.